We are working with PHA based nanocarriers with targeting capability for drug delivery to the tumors to enhance the therapeutic efficacy and reduce the side effects relative to conventional therapeutics. These nanocarriers have advantage over drug-delivery methods which have been developed using polymers as drug carriers as they can effectively deliver the drug to a target site and thus increase the therapeutic benefit, while minimizing side effects